This document provides methods and materials involved in assessing prostate cancer recurrence and reducing mesotrypsin activity. For example, methods and materials for using expression levels of PRSS3 nucleic acid to determine whether a prostate cancer patient having undergone prostatectomy is likely to experience prostate cancer recurrence are provided. In addition, methods and materials for reducing mesotrypsin activity are provided.